Ignite Creation Date:
2024-05-06 @ 6:21 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05631795
Status:
RECRUITING
Last Update Posted:
2024-03-20
First Post:
2022-11-21
Brief Title:
Study to Assess the Safety of Alpelisib Plus Fulvestrant in Men and Post-menopausal Women With HR-positive HER2-negative Advanced Breast Cancer aBC With PIK3CA Mutation Whose Disease Progressed on or After Endocrine Treatment
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis